- Home
- NXGL vs ISPC Comparison
NXGL vs ISPC Comparison
Compare NXGL & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | ISPC |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.2M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NXGL | ISPC |
|---|---|---|
| Price | $3.94 | $0.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 595.0K | 59.3K |
| Earning Date | 11-10-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.00 | ★ 87.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,421,000.00 | $1,928,998.00 |
| Revenue This Year | $38.23 | $638.10 |
| Revenue Next Year | $53.72 | $17.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.46 | N/A |
| 52 Week Low | $0.15 | $0.79 |
| 52 Week High | $214.40 | $115.00 |
Technical Indicators
Market Signals| Indicator | NXGL | ISPC |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 27.75 |
| Support Level | $3.12 | N/A |
| Resistance Level | $7.25 | $1.15 |
| Average True Range (ATR) | 0.92 | 0.07 |
| MACD | 0.32 | 0.01 |
| Stochastic Oscillator | 15.75 | 9.14 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.